Laurus Labs Q2 FY26 Earnings: Strong Margin Comeback, CDMO Drives Growth

Understand how Laurus Labs’ shift toward CDMO and specialty pharma is improving profitability and long-term growth outlook amid margin recovery. Laurus Labs delivered a strong set of numbers for Q2 FY26, reflecting a turnaround in profitability and operational leverage. Key Highlights: Revenue: ₹1,570 crore, up 31% YoY EBITDA: ₹389 crore; margin improved to 24.8% (vs 14.3% YoY) Net Profit: ₹163 crore, up over 11x YoY Gross Margin: 59.4%, up 430 bps YoY Business Drivers: CDMO segment (Contract Development & Manufacturing) saw strong traction — now a key growth engine. Formulations and API businesses improved with steady demand from ARV and non-ARV categories. New facilities under construction — Gene & ADC unit in Hyderabad and fermentation plant in Vizag — to enhance future capacity. What It Means for Investors: The shift from generic-heavy revenues to high-margin CDMO is paying off. Margin expansion signals better cost control and improving business mix. Continued investments suggest management confidence in sustainable growth. To Watch: Execution of new facilities and project pipeline. Pricing pressure in generic APIs. Cash flow trends amid heavy capex. Investor Takeaway: Laurus Labs is steadily transforming into a high-margin, innovation-led pharma company. While execution risk remains, its CDMO progress and margin recovery make it a promising long-term story.